Combination therapy for relapsed mantle cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new combination of two targeted drugs (ICP-248 and orelabrutinib) against a single targeted drug (pirtobrutinib) for people with mantle cell lymphoma that has come back or stopped responding to treatment. The goal is to see which approach works better and is safer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have mantle cell lymphoma that has returned or not responded to previous treatment.
- You need to have had an issue with or could not tolerate a BTK inhibitor (like ibrutinib) in the past.
- You should not have had a stem cell transplant or CAR-T therapy within the last 3 months (or any allogeneic transplant ever).
- You must not have severe heart disease, bleeding disorders, or other active cancers within the last 2 years.
- You must not have active infections, autoimmune diseases, or central nervous system lymphoma.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of two targeted drugs, orelabrutinib and rituximab, as a first treatment for mantle cell lymphoma (MCL). Some patients may also get a stem cell transplant. The goal is to see how well this approach works.
This trial tests a combination of three drugs (orelabrutinib, lisaftoclax, and rituximab) for people with mantle cell lymphoma who have not had treatment before and have high-risk features. The goal is to see if this combination works better than standard treatments.
This trial tests adding the targeted therapy orelabrutinib (a BTK inhibitor) to standard chemotherapy (bendamustine) and immunotherapy (rituximab) for people with high-risk mantle cell lymphoma who have not had treatment before. The goal is to see if the combination works better at controlling the cancer.
This trial tests a new combination of drugs (orelabrutinib plus BR) compared to BR alone for people with newly diagnosed mantle cell lymphoma who have not had treatment before. It may be an option if you are older or not able to have a stem cell transplant.
This trial tests a new drug combination (pirtobrutinib plus rituximab) for people with mantle cell lymphoma who have not yet received any treatment and do not have symptoms. The goal is to see if the combination is safe and effective.
This Phase 2 trial tests how well the combination of pirtobrutinib and venetoclax works for people with mantle cell lymphoma that has come back or did not respond to treatment. It’s meant to help shrink the lymphoma and improve outcomes after prior therapies.
Hear when a new Relapsed or Refractory Mantle Cell Lymphoma (MCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.